Counterpoint Mutual Funds LLC purchased a new position in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 33,819 shares of the life sciences company's stock, valued at approximately $415,000.
A number of other hedge funds have also recently bought and sold shares of the business. Principal Financial Group Inc. raised its position in shares of Integra LifeSciences by 2.5% in the 1st quarter. Principal Financial Group Inc. now owns 433,924 shares of the life sciences company's stock valued at $9,542,000 after purchasing an additional 10,492 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Integra LifeSciences in the first quarter worth $251,000. Victory Capital Management Inc. raised its holdings in Integra LifeSciences by 1,067.6% in the first quarter. Victory Capital Management Inc. now owns 147,982 shares of the life sciences company's stock valued at $3,254,000 after acquiring an additional 135,308 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Integra LifeSciences by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock valued at $872,000 after acquiring an additional 1,437 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Integra LifeSciences by 3,595.1% during the 1st quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company's stock worth $5,140,000 after acquiring an additional 22,721 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.
Integra LifeSciences Price Performance
IART opened at $13.97 on Wednesday. The company has a market capitalization of $1.09 billion, a P/E ratio of -2.14 and a beta of 1.20. The company has a 50-day moving average of $13.90 and a 200-day moving average of $15.10. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. Integra LifeSciences Holdings Corporation has a 1-year low of $11.06 and a 1-year high of $27.13.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. The business had revenue of $415.61 million during the quarter, compared to the consensus estimate of $395.06 million. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The company's revenue for the quarter was down .6% compared to the same quarter last year. During the same period last year, the firm earned $0.63 earnings per share. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Equities analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.
Integra LifeSciences Profile
(
Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
